Fig. 1 | Scientific Reports

Fig. 1

From: Nanocarrier mediated DOX/siRNA targeted co-delivery for synergistic treatment of cutaneous melanoma in outdoor athletes

Fig. 1

Cytotoxicity of FBqS NPs, siRNAIGF1R/FBqS NPs, free DOX, DOX/FBqS NPs and siRNAIGF1R/DOX/FBqS NPs against A375 cells by MTT assay (a) and FCM assay (b). The contents of FBqS NPs are about 13.3 mg/l, 26.7 mg/l, 40 mg/l, 53.3 mg/l, 66.6 mg/l, 80 mg/l, 93.3 mg/l and 106.6 mg/l, respectively corresponding to concentrations of DOX from 1 to 8 mg/l and siRNAIGF1R from 0.3 to 2.4 mg/l in (a); Wound healing images (c) and rate (d) of A375 cells incubated separately with different drug formulations at constant drugs concentrations, cells images were taken under 20× magnification; Western blotting result of IGF1R protein expression levels in A375 cells incubated with different doses of siRNAIGF1R/FBqS NPs for 48 h, β-actin protein was used as the loading control (e), original image is presented in Supplementary Fig. S4. *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page